CLN — Celon Pharma SA Cashflow Statement
0.000.00%
Last trade - 00:00
- PLN766.87m
- PLN681.53m
- PLN194.59m
- 70
- 16
- 53
- 40
2018 December 31st | 2019 December 31st | R2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | PAS | PAS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 29.7 | 11.9 | -5.59 | -15.1 | -36.4 |
Depreciation | |||||
Non-Cash Items | 0.101 | -0.504 | 0.767 | 3.63 | -4.62 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -18.8 | -37.1 | 44.8 | 14.1 | -7.73 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Net Change in Other Assets & Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | 28.2 | -5.05 | 71.7 | 44 | -4.7 |
Capital Expenditures | -67.5 | -65 | -99.5 | -41.4 | -33.9 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -5.28 | -2.78 | 46.2 | -79.7 | 2.43 |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -72.7 | -67.7 | -53.3 | -121 | -31.5 |
Financing Cash Flow Items | 0.098 | -0.174 | -0.586 | -14.3 | -1.5 |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -8.85 | -8.52 | 4.25 | 181 | -28.7 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -53.4 | -81.3 | 22.7 | 104 | -64.9 |